F-box and leucine-rich repeat protein 20 (FBXL20)

F-box and leucine-rich repeat protein 20 (FBXL20) is a member of the F-box protein family, characterized by an F-box motif and leucine-rich repeat (LRR) domains[1]. As a substrate-recognition component of the SCF (SKP1-CUL1-F-box) E3 ubiquitin ligase complex, FBXL20 targets specific proteins for polyubiquitination and subsequent proteasomal degradation[1][2]. FBXL20 has key roles in regulating apoptosis by promoting the degradation of proapoptotic proteins such as PUMA and BAX, an activity linked to the promotion of tumor cell survival and malignancy, particularly in breast cancer[2]. Its function is posttranslational and largely independent of p53 status, and is specifically linked to the AKT1 signaling pathway, which modulates substrate phosphorylation for FBXL20-mediated degradation[2]. The molecule is intracellular, with widespread expression patterns, and shares structural and functional similarity with other F-box/LRR proteins[1][2][4][5]. FBXL20 is not currently associated with clinically validated drugs or biomarkers but is considered a promising potential therapeutic target for sensitizing tumors to apoptosis in combination with chemotherapy[2].

Other names

F-box/LRR-repeat protein 20FBL2MGC15482Fbl2Fbl20F-box/LRR-repeat protein 2-likeF-box protein FBL2

Targeting FBXL20 may stabilize proapoptotic proteins (PUMA and BAX), promoting apoptosis in cancer cells[2]. Drugs inhibiting FBXL20’s E3 ligase activity would block proteasomal degradation of its substrates[2].